Tag:

cancer drugs

Latest Headlines

Latest Headlines

Payers think they can squeeze prices on cancer immunotherapies? Not so fast, analyst says

Looking for an antidote to all the payer chest-thumping about cancer drug prices? Here's some news to suit pharma, at least when it comes to cancer immunotherapies. One big distinction in health insurance--between medicines patients take at home and those they receive at doctors' offices--should put a crimp in payers' efforts to squeeze out discounts on PD-1 and PD-L1 therapies.

UPDATED: Merck cancer drugs and Sanofi, Amgen cardio meds have formularies on high alert

U.S. drug payers have been able to beat back high prices for some COPD and diabetes drugs, much to the chagrin of GlaxoSmithKline and Sanofi. But several new categories promise to break out in a big way, and we are not talking just about hepatitis C drugs.

ASCO proposes cancer drug scorecard, with some scary examples for Big Pharma

​The American Society of Clinical Oncology promised a rating scale for cancer drugs--and now, it has delivered. Let the blowback begin.

UPDATED: Blockbuster-to-be cancer meds outclass other big launches--except Sovaldi and statins

No question, immuno-oncology drugs are the hottest tickets in cancer--and among the hottest across the board. But PD-1/PD-L1 treatments, including Merck & Co.'s Keytruda and Bristol-Myers Squibb's Opdivo, aren't the first to bear big sales expectations. How do immuno-oncology forecasts stack up against other notable drug launches?

Top oncologist joins chorus of pricing critics in high-profile ASCO speech

Pharma types are getting a wee bit defensive about critics' attacks on cancer drug prices, if response to  FiercePharma 's recent coverage is any indication. But the criticism just keeps on coming, even as drugmakers work with payers behind the scenes on mutually acceptable pricing deals.

Stars of cancer meeting set to crack top 10 cancer sales by 2020

The buzz about bigger-and-better cancer drug sales abounds at the American Society of Clinical Oncology's annual meeting. But which oncology meds are actually tipped to make major gains between now and the end of the decade?

Australia budget is a showdown on cancer drug funding, safety net reach

An Australia government proposal to trim the national drug-coverage budget for innovative drugs by 5%, or U.S.$2.36 billion, has invited a juggernaut of industry opposition already descending on the parliament. The reductions are aimed at the nation's leading drugs, including those for cancer.

No real rationale for rising cancer drug prices, JAMA researchers conclude

A recent analysis by National Institutes of Health researchers found that cancer drug prices aren't exactly linked to drug results. In fact, the study concludes, drugmakers are simply charging "what the market will bear."

England's Cancer Drugs Fund changes its tune, holds onto Novartis' Afinitor

England's Cancer Drugs Fund is backtracking in its decision to remove certain treatments from its list of covered drugs, agreeing to keep Novartis' cancer med Afinitor for two of the three indications for which it was supposed to be removed.

Can Valeant transform Dendreon's ailing Provenge into a viable cancer competitor?

Now that Valeant has officially nabbed Dendreon's cancer vaccine Provenge, the Canadian drugmaker will have to nurse the treatment to health.